Maxwell Biosciences (688062.SH): Clinical trial application for injectable 6MW5311 approved by the National Medical Products Administration

Wisdom Financial APP News, Myway Bio (688062.SH) announced that recently, the company has received the "Drug Clinical Trial Approval Letter" issued by the National Medical Products Administration. The clinical trial application for the indication of injection 6MW5311 for hematologic malignancies (acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM)) has been approved.